<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02168842</url>
  </required_header>
  <id_info>
    <org_study_id>STEADY-PD III</org_study_id>
    <secondary_id>U01NS080818-01A1</secondary_id>
    <secondary_id>U01NS080840-01A1</secondary_id>
    <nct_id>NCT02168842</nct_id>
  </id_info>
  <brief_title>Efficacy of Isradipine in Early Parkinson Disease</brief_title>
  <official_title>Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Michael J. Fox Foundation for Parkinson's Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Parkinson Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether treatment with isradipine is effective in
      slowing the progression of Parkinson disease disability.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will enroll 336 participants in this multi-center study at approximately 56 sites
      across the US and Canada. In this study, we are comparing 10 mg of Isradipine to Placebo for
      treatment of newly diagnosed PD patients. Isradipine has been approved by the Food and Drug
      Administration (FDA) to treat high blood pressure but is considered investigational in this
      study, as it has not been approved for use in patients with PD.Isradipine can affect the
      function of specialized channels that are present in the types of brain cells that are
      affected in PD patient. These cells are usually responsible for making dopamine, which is
      depleted in patients with PD. Isradipine may block the damage caused by the flow of certain
      chemicals through these channels. Laboratory data has showed that Isradipine may prevent the
      development of Parkinson-like symptoms in animal studies. Isradipine has been evaluated in
      some patients with PD. The first study with isradipine controlled release (CR) in patients
      with early PD and normal blood pressure found that the drug was reasonably well tolerated and
      safe. The controlled release formulation of isradipine is not available for use and therefore
      this study is using the immediate release formulation. Eligible participants will be followed
      for up to 36 months and will be expected to complete 12 in-person visits and 4 telephone
      visits. The study visits will include clinical assessment of motor, neuropsychiatric and
      cognitive testing as well as collection of blood and urine samples. Study drug will taken
      twice daily, in the morning and in the evening with or without food. Prior to taking study
      drug, study participants will be required to take their blood pressure with a home blood
      pressure device provided to them for use in this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2014</start_date>
  <completion_date type="Actual">November 2018</completion_date>
  <primary_completion_date type="Actual">November 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adjusted Mean Change in Total Unified Parkinson Disease Rating Scale (UPDRS) Score</measure>
    <time_frame>Baseline to 36 months of treatment</time_frame>
    <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the total (Part I-III) UPDRS score in the active treatment arm versus placebo between the baseline and 36 month visit. The change of UPDRS ranges from -30 to 80, larger value shows more disability from PD.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adjusted Mean Change in Adjusted UPDRS Score</measure>
    <time_frame>Baseline to 36 months of treatment</time_frame>
    <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the adjusted UPDRS Score in the active treatment arm versus placebo between the baseline and 36 month visit. The change of adjusted UPDRS ranges from -100 to 150, larger value shows more disability from PD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change in LED</measure>
    <time_frame>Baseline to 36 months of treatment</time_frame>
    <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the LED(levodopa equivalent dose) in the active treatment arm versus placebo between the baseline and 36 month visit. The change of LED ranges from -100 to 3000, larger value shows more disability from PD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change in LED Cumulative</measure>
    <time_frame>Baseline to 36 months of treatment</time_frame>
    <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the LED(levodopa equivalent dose) cumulative in the active treatment arm versus placebo between the baseline and 36 month visit. The change of LED cumulative ranges from 0 to 1200000, larger value shows more disability from PD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change in UPDRS Part IV</measure>
    <time_frame>Baseline to 36 months of treatment</time_frame>
    <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the UPDRS Part IV in the active treatment arm versus placebo between the baseline and 36 month visit. The change in UPDRS Part IV ranges from -10 to 10, larger value shows more disability from PD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change in MDS-UPDRS nmEDL</measure>
    <time_frame>Baseline to 36 months of treatment</time_frame>
    <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the MDS-UPDRS nmEDL(Non-Motor Experiences of Daily Living) in the active treatment arm versus placebo between the baseline and 36 month visit. The change in MDS-UPDRS nmEDL ranges from -6 to 10, larger value shows more disability from PD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change in MDS-UPDRS mEDL</measure>
    <time_frame>Baseline to 36 months of treatment</time_frame>
    <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the MDS-UPDRS mEDL(Motor Experiences of Daily Living) in the active treatment arm versus placebo between the baseline and 36 month visit. The change in MDS-UPDRS mEDL ranges from -8 to 35, larger value shows more disability from PD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change in UPDRS Score to 1 Year</measure>
    <time_frame>Baseline to 12 months of treatment</time_frame>
    <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the MDS-UPDRS nmEDL(Non-Motor Experiences of Daily Living) in the active treatment arm versus placebo between the baseline and 12 month visit. The change of UPDRS ranges from -22 to 23, larger value shows more disability from PD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change in UPDRS Part II</measure>
    <time_frame>Baseline to 36 months of treatment</time_frame>
    <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the UPDRS Part II (ADL Function) in the active treatment arm versus placebo between the baseline and 36 month visit. The change in UPDRS Part II ranges from -12 to 19, larger value shows more disability from PD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change in UPDRS Part III OFF</measure>
    <time_frame>Baseline to 36 months of treatment</time_frame>
    <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the UPDRS Part III OFF rating in the active treatment arm versus placebo between the baseline and 36 month visit. The change in UPDRS Part III OFF ranges from -30 to 100, larger value shows more disability from PD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change in SE/ADL</measure>
    <time_frame>Baseline to 36 months of treatment</time_frame>
    <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the SE/ADL in the active treatment arm versus placebo between the baseline and 36 month visit. The change of UPDRS ranges from -70 to 20, larger value shows improvement of PD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change in Modified Rankin Score</measure>
    <time_frame>Baseline to 36 months of treatment</time_frame>
    <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the Modified Rankin Score in the active treatment arm versus placebo between the baseline and 36 month visit. The change in Modified Rankin Score ranges from -1 to 3, larger value shows worsening of conditions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change in MoCA Score</measure>
    <time_frame>Baseline to 36 months of treatment</time_frame>
    <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the MoCA Score in the active treatment arm versus placebo between the baseline and 36 month visit. The change in MoCA Score ranges from -10 to 6, larger value shows improvement of conditions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change in PDQ39 Total Score</measure>
    <time_frame>Baseline to 36 months of treatment</time_frame>
    <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the PDQ39 Total Score in the active treatment arm versus placebo between the baseline and 36 month visit. The change in PDQ39 Total Score ranges from -16 to 44, larger value shows worsening of conditions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change in Ambulatory Capacity</measure>
    <time_frame>Baseline to 36 months of treatment</time_frame>
    <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the Ambulatory Capacity in the active treatment arm versus placebo between the baseline and 36 month visit. The change in Ambulatory Capacity ranges from -4 to 12, larger value shows worsening of conditions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change in BDI Total Score</measure>
    <time_frame>Baseline to 36 months of treatment</time_frame>
    <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the BDI Total Score in the active treatment arm versus placebo between the baseline and 36 month visit. The change in BDI Total Score ranges from -9 to 22, larger value shows worsening of conditions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk of Need for Antiparkinsonian Therapy</measure>
    <time_frame>Baseline to 36 months of treatment</time_frame>
    <description>Number of participants with need for Antiparkinsonian Therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk of Need for Dyskinesia</measure>
    <time_frame>Baseline to 36 months of treatment</time_frame>
    <description>Number of participants with need for Dyskinesia Therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk of Need for Fluctuations</measure>
    <time_frame>Baseline to 36 months of treatment</time_frame>
    <description>Number of participants with need for Fluctuations Therapy.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adjusted Mean Change in UPDRS PIGD Score</measure>
    <time_frame>Baseline to 36 months of treatment</time_frame>
    <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the UPDRS PIGD Score in the active treatment arm versus placebo between the baseline and 36 month visit. The change in UPDRS PIGD Score ranges from -1 to 3, larger value shows worsening of conditions.</description>
  </other_outcome>
  <other_outcome>
    <measure>Adjusted Mean Change in UPDRS Tremor Score</measure>
    <time_frame>Baseline to 36 months of treatment</time_frame>
    <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the UPDRS Tremor Score in the active treatment arm versus placebo between the baseline and 36 month visit. The change in UPDRS Tremor Score ranges from -1 to 2, larger value shows worsening of conditions.</description>
  </other_outcome>
  <other_outcome>
    <measure>Adjusted Mean Change in H/Y Stage</measure>
    <time_frame>Baseline to 36 months of treatment</time_frame>
    <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the H/Y Stage in the active treatment arm versus placebo between the baseline and 36 month visit. The change in H/Y Stage ranges from -1 to 3, larger value shows worsening of conditions.</description>
  </other_outcome>
  <other_outcome>
    <measure>Adjusted Mean Change in Levodopa</measure>
    <time_frame>Baseline to 36 months of treatment</time_frame>
    <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the Levodopa in the active treatment arm versus placebo between the baseline and 36 month visit. The change of LED ranges from -200 to 2000, larger value shows more disability from PD.</description>
  </other_outcome>
  <other_outcome>
    <measure>Adjusted Mean Change in Levodopa Cumulative</measure>
    <time_frame>Baseline to 36 months of treatment</time_frame>
    <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the Levodopa Cumulative in the active treatment arm versus placebo between the baseline and 36 month visit. The change of Levodopa cumulative ranges from 0 to 800000, larger value shows more disability from PD.</description>
  </other_outcome>
  <other_outcome>
    <measure>Adjusted Mean Change in Systolic BP, Seated</measure>
    <time_frame>Baseline to 36 months of treatment</time_frame>
    <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the Systolic BP, Seated in the active treatment arm versus placebo between the baseline and 36 month visit. The change in Systolic BP, Seated ranges from -65 to 50. larger value shows worsening of conditions.</description>
  </other_outcome>
  <other_outcome>
    <measure>Adjusted Mean Change in Diastolic BP, Seated</measure>
    <time_frame>Baseline to 36 months of treatment</time_frame>
    <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the Diastolic BP, Seated in the active treatment arm versus placebo between the baseline and 36 month visit. The change in Diastolic BP, Seated ranges from -35 to 25. larger value shows worsening of conditions.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">336</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Isradipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral capsule of up to 5 mg of isradipine taken twice daily for 36 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (for Isradipine)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral capsule taken twice daily for 36 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isradipine</intervention_name>
    <description>Oral capsules Isradipine IR, up to 10 mg, taken twice daily</description>
    <arm_group_label>Isradipine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for Isradipine)</intervention_name>
    <description>Sugar Pill manufactured to look like Isradipine but has no active ingredients</description>
    <arm_group_label>Placebo (for Isradipine)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with early idiopathic PD (presence of at least two out of three cardinal
             manifestations of PD). If tremor is not present, subjects must have unilateral onset
             and persistent asymmetry of the symptoms

          -  Age equal or greater than 30 years at the time of diagnosis of PD

          -  Hoehn and Yahr stage less than or equal to 2

          -  Diagnosis of PD less than 3 years.

          -  Currently NOT receiving dopaminergic therapy (levodopa, dopamine agonist or MAO-B
             inhibitors) and NOT projected to require PD symptomatic therapy for at least 3 months
             from the baseline visit

          -  Use of amantadine and/or anticholinergics will be allowed provided that the dose is
             stable for 8 weeks prior to the baseline visit

          -  If subject is taking any central nervous system acting medications (e.g.,
             benzodiazepines, antidepressants, hypnotics) regimen must be stable for 30 days prior
             to the baseline visit

          -  Women of childbearing potential may enroll but must use a reliable measure of
             contraception and have a negative serum pregnancy test at the screening visit

        Exclusion Criteria:

          -  Subjects with a diagnosis of an atypical Parkinsonism

          -  Subjects unwilling or unable to give informed consent

          -  Exposure to dopaminergic PD therapy within 60 days prior to baseline visit or for
             consecutive 3 months or more at any point in the past

          -  History of clinically significant orthostatic hypotension or presence of orthostatic
             hypotension at the screening or baseline visit defined as greater than or equal to 20
             mmHg change in systolic BP and greater than or equal to 10 mmHg change in diastolic BP
             from sitting position to standing after 2 minutes, or baseline sitting BP less than
             90/60

          -  History of congestive heart failure

          -  Clinically significant bradycardia

          -  Presence of 2nd or 3rd degree atrioventricular block or other significant ECG
             abnormalities that in the investigator's opinion would compromise participation in
             study

          -  Clinically significant abnormalities in the Screening Visit laboratory studies or ECG

          -  Presence of other known medical or psychiatric comorbidity that in the investigator's
             opinion would compromise participation in the study

          -  Prior exposure to isradipine or other dihydropyridine calcium channel blockers within
             6 months of the baseline visit

          -  Subjects on greater than 2 concomitant antihypertensive medications. If a history of
             hypertension, then a maximum of 2 other antihypertensive agents will be allowed
             provided that the dosages of concomitant anti HTN therapy can be reduced/adjusted
             during the study based on the BP readings in consultation with the subject's primary
             care provider or cardiologist. Use of any concomitant calcium channel blockers will
             not be allowed from the baseline visit and for the duration of the study

          -  Use of grapefruit juice, ginkgo biloba, St. John's wort or ginseng will be prohibited
             starting from the screening visit and for the duration of the study (as they interfere
             with the metabolism of isradipine)

          -  Use of clarithromycin, telithromycin and erythromycin will be prohibited starting from
             the screening visit and for the duration of the study as the combination of
             clarithromycin, telithromycin or erythromycin and calcium channel blockers has been
             reported to be associated with increased risk of kidney and heart injury

          -  Presence of cognitive dysfunction defined by a Montreal Cognitive assessment (MoCA)
             score of less than 26 at screening

          -  Subjects with clinically significant depression as determined by a Beck Depression
             Inventory II (BDI) score greater than 15 at the screening visit

          -  History of exposure to typical or atypical antipsychotics or other dopamine blocking
             agents within 6 months prior to the baseline visit

          -  History of use of an investigational drug within 30 days prior to the screening visit

          -  History of brain surgery for PD

          -  Allergy/sensitivity to isradipine or its matching placebo or their formulations

          -  Pregnant or lactating woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tanya Simuni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Holloway, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Banner Sun Health Research Institute</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85315</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Parkinsons &amp; Movement Disorder Institute</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Movement Disorders Center</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Neurodegenerative Disorders</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Health Research &amp; Education Institute</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky Medical Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LSU Health Science Center</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston University Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan State University</name>
      <address>
        <city>East Lansing</city>
        <state>Michigan</state>
        <zip>48824</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Struthers Parkinson's Center</name>
      <address>
        <city>Golden Valley</city>
        <state>Minnesota</state>
        <zip>55427</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nevada School of Medicine</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlantic Neuroscience Institute</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <zip>07901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical College</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Quest Kingston</name>
      <address>
        <city>Kingston</city>
        <state>New York</state>
        <zip>12401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Medical College of Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>20021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Milton S Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Neurology Specialists</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23456</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Booth Gardner Parkinson's Care Center</name>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <zip>98034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>t6g 2g3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Civic Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4E9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Centre for Addiction and Mental Health</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>m3b 2s7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Western Hospital, University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM - Hopital Notre-Dame</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Affilie</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1J 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.steadypd3.com</url>
    <description>STEADY-PD III Study Website</description>
  </link>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>June 18, 2014</study_first_submitted>
  <study_first_submitted_qc>June 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2014</study_first_posted>
  <results_first_submitted>December 6, 2019</results_first_submitted>
  <results_first_submitted_qc>January 7, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 14, 2020</results_first_posted>
  <last_update_submitted>January 7, 2020</last_update_submitted>
  <last_update_submitted_qc>January 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Robert Holloway</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Parkinson</keyword>
  <keyword>Parkinson Disease</keyword>
  <keyword>Parkinson's Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isradipine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 31, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT02168842/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 1, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT02168842/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited from 57 Parkinson Study Group sites in North America from November 2014 through November 2015.</recruitment_details>
      <pre_assignment_details>413 patients were assessed for eligibility. 12 patients declined to participate and 65 patients were excluded (9 exclusionary medications, 2 other medical psychiatric or surgical, 5 disease too advanced, 6 diagnosis uncertain, 23 didn't meet other inclusion criteria, 20 other). 336 patients were enrolled and underwent randomization</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Isradipine</title>
          <description>Receive Isradipine 5 mg twice daily for 36 months. Isradipine: oral immediate-release capsule of Isradipine 10 mg per day.</description>
        </group>
        <group group_id="P2">
          <title>Placebo (for Isradipine)</title>
          <description>Receive placebo twice daily for 36 months. Placebo: Sugar Pill manufactured to look like Isradipine but has no active ingredients</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="170"/>
                <participants group_id="P2" count="166"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="162"/>
                <participants group_id="P2" count="158"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Isradipine</title>
          <description>Oral capsule of up to 5 mg of isradipine taken twice daily for 36 months.
Isradipine: Oral capsules Isradipine IR, up to 10 mg, taken twice daily</description>
        </group>
        <group group_id="B2">
          <title>Placebo (for Isradipine)</title>
          <description>Oral capsule taken twice daily for 36 months.
Placebo (for Isradipine): Sugar Pill manufactured to look like Isradipine but has no active ingredients</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="170"/>
            <count group_id="B2" value="166"/>
            <count group_id="B3" value="336"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="170"/>
                    <count group_id="B2" value="166"/>
                    <count group_id="B3" value="336"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.11" spread="8.73"/>
                    <measurement group_id="B2" value="61.61" spread="9.34"/>
                    <measurement group_id="B3" value="61.86" spread="9.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="170"/>
                    <count group_id="B2" value="166"/>
                    <count group_id="B3" value="336"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="106"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="170"/>
                    <count group_id="B2" value="166"/>
                    <count group_id="B3" value="336"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="166"/>
                    <measurement group_id="B2" value="160"/>
                    <measurement group_id="B3" value="326"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="170"/>
                    <count group_id="B2" value="166"/>
                    <count group_id="B3" value="336"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="159"/>
                    <measurement group_id="B2" value="149"/>
                    <measurement group_id="B3" value="308"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Enrolled patients were from 54 Parkinson Study Group sites in North America. 7 locate in Canada and 47 locate in United States.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="170"/>
                    <count group_id="B2" value="166"/>
                    <count group_id="B3" value="336"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="154"/>
                    <measurement group_id="B2" value="149"/>
                    <measurement group_id="B3" value="303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="170"/>
                    <count group_id="B2" value="166"/>
                    <count group_id="B3" value="336"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease Duration</title>
          <description>Months from diagnosis.</description>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="170"/>
                    <count group_id="B2" value="166"/>
                    <count group_id="B3" value="336"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.89" spread="8.13"/>
                    <measurement group_id="B2" value="10.56" spread="9.35"/>
                    <measurement group_id="B3" value="10.22" spread="8.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Family History of PD</title>
          <description>First degree relatives only</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="170"/>
                    <count group_id="B2" value="166"/>
                    <count group_id="B3" value="336"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Handedness</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="170"/>
                    <count group_id="B2" value="166"/>
                    <count group_id="B3" value="336"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Right</title>
                  <measurement_list>
                    <measurement group_id="B1" value="147"/>
                    <measurement group_id="B2" value="142"/>
                    <measurement group_id="B3" value="289"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Left</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mixed</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>On Symptomatic Therapy (Amantadine)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="170"/>
                    <count group_id="B2" value="166"/>
                    <count group_id="B3" value="336"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>On Symptomatic Therapy (Anticholinergics)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="170"/>
                    <count group_id="B2" value="166"/>
                    <count group_id="B3" value="336"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>UPDRS Total Score</title>
          <description>Baseline total Unified Parkinson Disease Rating Scale (UPDRS) score ranges from 0 to 52. Larger value stands for more disability from PD.</description>
          <population>One participant had missing baseline UPDRS</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="170"/>
                    <count group_id="B2" value="165"/>
                    <count group_id="B3" value="335"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.66" spread="8.64"/>
                    <measurement group_id="B2" value="22.58" spread="8.53"/>
                    <measurement group_id="B3" value="23.13" spread="8.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mental Scale</title>
          <description>Baseline UPDRS Mental (UPDRS Part I: Mentation, Behavior, and Mood) score ranges from 0 to 7. Larger value stands for more disability from PD.</description>
          <population>One participant had missing baseline UPDRS</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="170"/>
                    <count group_id="B2" value="165"/>
                    <count group_id="B3" value="335"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.61" spread="0.87"/>
                    <measurement group_id="B2" value="0.81" spread="1.21"/>
                    <measurement group_id="B3" value="0.71" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ADL Scale</title>
          <description>Baseline UPDRS ADL (Part II) score ranges from 0 to 16. Larger value stands for more disability from PD. UPDRS Part II: self-evaluation of the activities of daily life (ADLs) including speech, swallowing, handwriting, dressing, hygiene, falling, salivating, turning in bed, walking, and cutting food.</description>
          <population>One participant had missing baseline UPDRS</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="170"/>
                    <count group_id="B2" value="165"/>
                    <count group_id="B3" value="335"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.96" spread="2.88"/>
                    <measurement group_id="B2" value="5.45" spread="3.26"/>
                    <measurement group_id="B3" value="5.2" spread="3.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Motor Scale</title>
          <description>Baseline UPDRS Motor (Part III) score ranges from 0 to 42. Larger value stands for more disability from PD. UPDRS part III: clinician-scored monitored motor evaluation</description>
          <population>One participant had missing baseline UPDRS</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="170"/>
                    <count group_id="B2" value="165"/>
                    <count group_id="B3" value="335"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.08" spread="7.3"/>
                    <measurement group_id="B2" value="16.32" spread="6.53"/>
                    <measurement group_id="B3" value="17.21" spread="6.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>UPSDRS PIGD Score</title>
          <description>Baseline UPDRS PIGD score ranges from 0 to 1. Larger value stands for more disability from PD.</description>
          <population>One participant had missing baseline UPDRS PIGD Score</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="170"/>
                    <count group_id="B2" value="165"/>
                    <count group_id="B3" value="335"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.17" spread="0.19"/>
                    <measurement group_id="B2" value="0.17" spread="0.17"/>
                    <measurement group_id="B3" value="0.17" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>UPDRS Tremor Score</title>
          <description>Baseline UPDRS Tremor score ranges from 0 to 1.63. Larger value stands for more disability from PD.</description>
          <population>One participant had missing baseline UPDRS Tremor Score</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="170"/>
                    <count group_id="B2" value="165"/>
                    <count group_id="B3" value="335"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.51" spread="0.32"/>
                    <measurement group_id="B2" value="0.50" spread="0.29"/>
                    <measurement group_id="B3" value="0.51" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>H/Y Stage</title>
          <description>Hoehn and Yahr staging of severity of Parkinson's disease. Baseline H/Y stage ranges from 1 to 3. Larger value stands for more disability from PD.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="170"/>
                    <count group_id="B2" value="166"/>
                    <count group_id="B3" value="336"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.72" spread="0.46"/>
                    <measurement group_id="B2" value="1.6" spread="0.5"/>
                    <measurement group_id="B3" value="1.66" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>SE/ADL</title>
          <description>Schwab and England ADL scale. Baseline SE/ADL ranges from 40 to 100. Smaller value stands for more disability from PD.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="170"/>
                    <count group_id="B2" value="166"/>
                    <count group_id="B3" value="336"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94.44" spread="5.23"/>
                    <measurement group_id="B2" value="94.04" spread="6.8"/>
                    <measurement group_id="B3" value="94.24" spread="6.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Modified Rankin Score</title>
          <description>The modified Rankin Scale (mRS) measures the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. Baseline Modified Rankin score ranges from 0 to 2. Larger value stands for more disability from PD.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="170"/>
                    <count group_id="B2" value="166"/>
                    <count group_id="B3" value="336"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.09" spread="0.31"/>
                    <measurement group_id="B2" value="1.09" spread="0.33"/>
                    <measurement group_id="B3" value="1.09" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>MoCA Score</title>
          <description>Montreal Cognitive Assessment (MoCA) is one-page 30-point test to detect cognitive impairment. Baseline MoCA score ranges from 23 to 30. Higher scores indicate better cognition.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="170"/>
                    <count group_id="B2" value="166"/>
                    <count group_id="B3" value="336"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.14" spread="1.41"/>
                    <measurement group_id="B2" value="28.04" spread="1.29"/>
                    <measurement group_id="B3" value="28.09" spread="1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BDI Total Score</title>
          <description>Baseline Beck Depression Inventory (BDI) score ranges from 0 to 23. Higher scores indicate greater symptom severity.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="170"/>
                    <count group_id="B2" value="166"/>
                    <count group_id="B3" value="336"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.09" spread="3.71"/>
                    <measurement group_id="B2" value="4.8" spread="4.29"/>
                    <measurement group_id="B3" value="4.44" spread="4.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PDQ39 Total Score</title>
          <description>Parkinson's Disease Questionnaire-39 is a 39-item self-report questionnaire, which assesses Parkinson's disease-specific health related quality over the past month. Baseline PDQ 39 score ranges from 0 to 52. Lower score shows better quality of life.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="170"/>
                    <count group_id="B2" value="166"/>
                    <count group_id="B3" value="336"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.13" spread="6.15"/>
                    <measurement group_id="B2" value="9.08" spread="8.52"/>
                    <measurement group_id="B3" value="8.10" spread="7.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic BP, Seated</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="170"/>
                    <count group_id="B2" value="166"/>
                    <count group_id="B3" value="336"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="128.12" spread="17.17"/>
                    <measurement group_id="B2" value="127.69" spread="14.6"/>
                    <measurement group_id="B3" value="127.91" spread="15.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic BP, Seated</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="170"/>
                    <count group_id="B2" value="166"/>
                    <count group_id="B3" value="336"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76.55" spread="9.72"/>
                    <measurement group_id="B2" value="77.83" spread="8.52"/>
                    <measurement group_id="B3" value="77.18" spread="9.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adjusted Mean Change in Total Unified Parkinson Disease Rating Scale (UPDRS) Score</title>
        <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the total (Part I-III) UPDRS score in the active treatment arm versus placebo between the baseline and 36 month visit. The change of UPDRS ranges from -30 to 80, larger value shows more disability from PD.</description>
        <time_frame>Baseline to 36 months of treatment</time_frame>
        <population>Intention-to-treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Isradipine</title>
            <description>Oral capsule of up to 5 mg of isradipine taken twice daily for 36 months.
Isradipine: Oral capsules Isradipine IR, up to 10 mg, taken twice daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo (for Isradipine)</title>
            <description>Oral capsule taken twice daily for 36 months.
Placebo (for Isradipine): Sugar Pill manufactured to look like Isradipine but has no active ingredients</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change in Total Unified Parkinson Disease Rating Scale (UPDRS) Score</title>
          <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the total (Part I-III) UPDRS score in the active treatment arm versus placebo between the baseline and 36 month visit. The change of UPDRS ranges from -30 to 80, larger value shows more disability from PD.</description>
          <population>Intention-to-treat (ITT) population</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.99" lower_limit="0.95" upper_limit="5.03"/>
                    <measurement group_id="O2" value="3.26" lower_limit="1.25" upper_limit="5.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adjusted Mean Change in Adjusted UPDRS Score</title>
        <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the adjusted UPDRS Score in the active treatment arm versus placebo between the baseline and 36 month visit. The change of adjusted UPDRS ranges from -100 to 150, larger value shows more disability from PD.</description>
        <time_frame>Baseline to 36 months of treatment</time_frame>
        <population>Intention-to-treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Isradipine</title>
            <description>Receive Isradipine 5 mg twice daily for 36 months. Isradipine: oral immediate-release capsule of Isradipine 10 mg per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (for Isradipine)</title>
            <description>Receive placebo twice daily for 36 months. Placebo: Sugar Pill manufactured to look like Isradipine but has no active ingredients</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change in Adjusted UPDRS Score</title>
          <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the adjusted UPDRS Score in the active treatment arm versus placebo between the baseline and 36 month visit. The change of adjusted UPDRS ranges from -100 to 150, larger value shows more disability from PD.</description>
          <population>Intention-to-treat (ITT) population</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.49" lower_limit="11.32" upper_limit="15.66"/>
                    <measurement group_id="O2" value="13.85" lower_limit="11.72" upper_limit="15.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change in LED</title>
        <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the LED(levodopa equivalent dose) in the active treatment arm versus placebo between the baseline and 36 month visit. The change of LED ranges from -100 to 3000, larger value shows more disability from PD.</description>
        <time_frame>Baseline to 36 months of treatment</time_frame>
        <population>Intention-to-treat (ITT) population. One participant had missing baseline UPDRS sections while had finished baseline LED measurement. So LED had 1 more observation than primary outcomes.</population>
        <group_list>
          <group group_id="O1">
            <title>Isradipine</title>
            <description>Receive Isradipine 5 mg twice daily for 36 months. Isradipine: oral immediate-release capsule of Isradipine 10 mg per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (for Isradipine)</title>
            <description>Receive placebo twice daily for 36 months. Placebo: Sugar Pill manufactured to look like Isradipine but has no active ingredients</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change in LED</title>
          <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the LED(levodopa equivalent dose) in the active treatment arm versus placebo between the baseline and 36 month visit. The change of LED ranges from -100 to 3000, larger value shows more disability from PD.</description>
          <population>Intention-to-treat (ITT) population. One participant had missing baseline UPDRS sections while had finished baseline LED measurement. So LED had 1 more observation than primary outcomes.</population>
          <units>mg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="389" lower_limit="337" upper_limit="441"/>
                    <measurement group_id="O2" value="375" lower_limit="325" upper_limit="426"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change in LED Cumulative</title>
        <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the LED(levodopa equivalent dose) cumulative in the active treatment arm versus placebo between the baseline and 36 month visit. The change of LED cumulative ranges from 0 to 1200000, larger value shows more disability from PD.</description>
        <time_frame>Baseline to 36 months of treatment</time_frame>
        <population>Intention-to-treat (ITT) population. One participant had missing baseline UPDRS sections while had finished baseline LED Cumulative measurement. So LED Cumulative had 1 more observation than primary outcomes.</population>
        <group_list>
          <group group_id="O1">
            <title>Isradipine</title>
            <description>Receive Isradipine 5 mg twice daily for 36 months. Isradipine: oral immediate-release capsule of Isradipine 10 mg per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (for Isradipine)</title>
            <description>Receive placebo twice daily for 36 months. Placebo: Sugar Pill manufactured to look like Isradipine but has no active ingredients</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change in LED Cumulative</title>
          <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the LED(levodopa equivalent dose) cumulative in the active treatment arm versus placebo between the baseline and 36 month visit. The change of LED cumulative ranges from 0 to 1200000, larger value shows more disability from PD.</description>
          <population>Intention-to-treat (ITT) population. One participant had missing baseline UPDRS sections while had finished baseline LED Cumulative measurement. So LED Cumulative had 1 more observation than primary outcomes.</population>
          <units>mg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="676" lower_limit="588" upper_limit="765"/>
                    <measurement group_id="O2" value="697" lower_limit="611" upper_limit="784"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change in UPDRS Part IV</title>
        <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the UPDRS Part IV in the active treatment arm versus placebo between the baseline and 36 month visit. The change in UPDRS Part IV ranges from -10 to 10, larger value shows more disability from PD.</description>
        <time_frame>Baseline to 36 months of treatment</time_frame>
        <population>Intention-to-treat (ITT) population. 46 patients had missing measures at the visit of 36 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Isradipine</title>
            <description>Receive Isradipine 5 mg twice daily for 36 months. Isradipine: oral immediate-release capsule of Isradipine 10 mg per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (for Isradipine)</title>
            <description>Receive placebo twice daily for 36 months. Placebo: Sugar Pill manufactured to look like Isradipine but has no active ingredients</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change in UPDRS Part IV</title>
          <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the UPDRS Part IV in the active treatment arm versus placebo between the baseline and 36 month visit. The change in UPDRS Part IV ranges from -10 to 10, larger value shows more disability from PD.</description>
          <population>Intention-to-treat (ITT) population. 46 patients had missing measures at the visit of 36 months.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.18" lower_limit="0.9" upper_limit="1.46"/>
                    <measurement group_id="O2" value="1.07" lower_limit="0.8" upper_limit="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change in MDS-UPDRS nmEDL</title>
        <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the MDS-UPDRS nmEDL(Non-Motor Experiences of Daily Living) in the active treatment arm versus placebo between the baseline and 36 month visit. The change in MDS-UPDRS nmEDL ranges from -6 to 10, larger value shows more disability from PD.</description>
        <time_frame>Baseline to 36 months of treatment</time_frame>
        <population>Intention-to-treat (ITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Isradipine</title>
            <description>Receive Isradipine 5 mg twice daily for 36 months. Isradipine: oral immediate-release capsule of Isradipine 10 mg per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (for Isradipine)</title>
            <description>Receive placebo twice daily for 36 months. Placebo: Sugar Pill manufactured to look like Isradipine but has no active ingredients</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change in MDS-UPDRS nmEDL</title>
          <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the MDS-UPDRS nmEDL(Non-Motor Experiences of Daily Living) in the active treatment arm versus placebo between the baseline and 36 month visit. The change in MDS-UPDRS nmEDL ranges from -6 to 10, larger value shows more disability from PD.</description>
          <population>Intention-to-treat (ITT) population.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.93" lower_limit="1.28" upper_limit="2.59"/>
                    <measurement group_id="O2" value="1.76" lower_limit="1.13" upper_limit="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change in MDS-UPDRS mEDL</title>
        <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the MDS-UPDRS mEDL(Motor Experiences of Daily Living) in the active treatment arm versus placebo between the baseline and 36 month visit. The change in MDS-UPDRS mEDL ranges from -8 to 35, larger value shows more disability from PD.</description>
        <time_frame>Baseline to 36 months of treatment</time_frame>
        <population>Intention-to-treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Isradipine</title>
            <description>Receive Isradipine 5 mg twice daily for 36 months. Isradipine: oral immediate-release capsule of Isradipine 10 mg per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (for Isradipine)</title>
            <description>Receive placebo twice daily for 36 months. Placebo: Sugar Pill manufactured to look like Isradipine but has no active ingredients</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change in MDS-UPDRS mEDL</title>
          <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the MDS-UPDRS mEDL(Motor Experiences of Daily Living) in the active treatment arm versus placebo between the baseline and 36 month visit. The change in MDS-UPDRS mEDL ranges from -8 to 35, larger value shows more disability from PD.</description>
          <population>Intention-to-treat (ITT) population</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.32" lower_limit="1.52" upper_limit="3.12"/>
                    <measurement group_id="O2" value="2.57" lower_limit="1.78" upper_limit="3.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change in UPDRS Score to 1 Year</title>
        <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the MDS-UPDRS nmEDL(Non-Motor Experiences of Daily Living) in the active treatment arm versus placebo between the baseline and 12 month visit. The change of UPDRS ranges from -22 to 23, larger value shows more disability from PD.</description>
        <time_frame>Baseline to 12 months of treatment</time_frame>
        <population>Intention-to-treat (ITT) population. There were 169 patients in Isradipine group and 165 in placebo group who reached 1-year visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Isradipine</title>
            <description>Receive Isradipine 5 mg twice daily for 36 months. Isradipine: oral immediate-release capsule of Isradipine 10 mg per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (for Isradipine)</title>
            <description>Receive placebo twice daily for 36 months. Placebo: Sugar Pill manufactured to look like Isradipine but has no active ingredients</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change in UPDRS Score to 1 Year</title>
          <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the MDS-UPDRS nmEDL(Non-Motor Experiences of Daily Living) in the active treatment arm versus placebo between the baseline and 12 month visit. The change of UPDRS ranges from -22 to 23, larger value shows more disability from PD.</description>
          <population>Intention-to-treat (ITT) population. There were 169 patients in Isradipine group and 165 in placebo group who reached 1-year visit.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="169"/>
                <count group_id="O2" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.65" lower_limit="3.59" upper_limit="5.70"/>
                    <measurement group_id="O2" value="5.3" lower_limit="4.25" upper_limit="6.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change in UPDRS Part II</title>
        <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the UPDRS Part II (ADL Function) in the active treatment arm versus placebo between the baseline and 36 month visit. The change in UPDRS Part II ranges from -12 to 19, larger value shows more disability from PD.</description>
        <time_frame>Baseline to 36 months of treatment</time_frame>
        <population>Intention-to-treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Isradipine</title>
            <description>Receive Isradipine 5 mg twice daily for 36 months. Isradipine: oral immediate-release capsule of Isradipine 10 mg per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (for Isradipine)</title>
            <description>Receive placebo twice daily for 36 months. Placebo: Sugar Pill manufactured to look like Isradipine but has no active ingredients</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change in UPDRS Part II</title>
          <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the UPDRS Part II (ADL Function) in the active treatment arm versus placebo between the baseline and 36 month visit. The change in UPDRS Part II ranges from -12 to 19, larger value shows more disability from PD.</description>
          <population>Intention-to-treat (ITT) population</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="1.63" upper_limit="3.97"/>
                    <measurement group_id="O2" value="2.5" lower_limit="1.83" upper_limit="3.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change in UPDRS Part III OFF</title>
        <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the UPDRS Part III OFF rating in the active treatment arm versus placebo between the baseline and 36 month visit. The change in UPDRS Part III OFF ranges from -30 to 100, larger value shows more disability from PD.</description>
        <time_frame>Baseline to 36 months of treatment</time_frame>
        <population>Intention-to-treat (ITT) population. 58 patients had missing measures at the visit of 36 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Isradipine</title>
            <description>Receive Isradipine 5 mg twice daily for 36 months. Isradipine: oral immediate-release capsule of Isradipine 10 mg per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (for Isradipine)</title>
            <description>Receive placebo twice daily for 36 months. Placebo: Sugar Pill manufactured to look like Isradipine but has no active ingredients</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change in UPDRS Part III OFF</title>
          <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the UPDRS Part III OFF rating in the active treatment arm versus placebo between the baseline and 36 month visit. The change in UPDRS Part III OFF ranges from -30 to 100, larger value shows more disability from PD.</description>
          <population>Intention-to-treat (ITT) population. 58 patients had missing measures at the visit of 36 months.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.60" lower_limit="3.05" upper_limit="6.14"/>
                    <measurement group_id="O2" value="4.50" lower_limit="3.02" upper_limit="5.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change in SE/ADL</title>
        <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the SE/ADL in the active treatment arm versus placebo between the baseline and 36 month visit. The change of UPDRS ranges from -70 to 20, larger value shows improvement of PD.</description>
        <time_frame>Baseline to 36 months of treatment</time_frame>
        <population>Intention-to-treat (ITT) population. One participant had missing baseline UPDRS sections while had finished baseline SE/ADL measurement. So SE/ADL had 1 more observation than primary outcomes.</population>
        <group_list>
          <group group_id="O1">
            <title>Isradipine</title>
            <description>Receive Isradipine 5 mg twice daily for 36 months. Isradipine: oral immediate-release capsule of Isradipine 10 mg per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (for Isradipine)</title>
            <description>Receive placebo twice daily for 36 months. Placebo: Sugar Pill manufactured to look like Isradipine but has no active ingredients</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change in SE/ADL</title>
          <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the SE/ADL in the active treatment arm versus placebo between the baseline and 36 month visit. The change of UPDRS ranges from -70 to 20, larger value shows improvement of PD.</description>
          <population>Intention-to-treat (ITT) population. One participant had missing baseline UPDRS sections while had finished baseline SE/ADL measurement. So SE/ADL had 1 more observation than primary outcomes.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.14" lower_limit="-5.30" upper_limit="-2.98"/>
                    <measurement group_id="O2" value="-4.41" lower_limit="-5.54" upper_limit="-3.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change in Modified Rankin Score</title>
        <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the Modified Rankin Score in the active treatment arm versus placebo between the baseline and 36 month visit. The change in Modified Rankin Score ranges from -1 to 3, larger value shows worsening of conditions.</description>
        <time_frame>Baseline to 36 months of treatment</time_frame>
        <population>Intention-to-treat (ITT) population. One participant had missing baseline measurement for primary efficacy while had finished baseline Modified Rankin Score. So Modified Rankin Score had 1 more observation than primary outcomes.</population>
        <group_list>
          <group group_id="O1">
            <title>Isradipine</title>
            <description>Receive Isradipine 5 mg twice daily for 36 months. Isradipine: oral immediate-release capsule of Isradipine 10 mg per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (for Isradipine)</title>
            <description>Receive placebo twice daily for 36 months. Placebo: Sugar Pill manufactured to look like Isradipine but has no active ingredients</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change in Modified Rankin Score</title>
          <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the Modified Rankin Score in the active treatment arm versus placebo between the baseline and 36 month visit. The change in Modified Rankin Score ranges from -1 to 3, larger value shows worsening of conditions.</description>
          <population>Intention-to-treat (ITT) population. One participant had missing baseline measurement for primary efficacy while had finished baseline Modified Rankin Score. So Modified Rankin Score had 1 more observation than primary outcomes.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" lower_limit="0.07" upper_limit="0.28"/>
                    <measurement group_id="O2" value="0.29" lower_limit="0.18" upper_limit="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change in MoCA Score</title>
        <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the MoCA Score in the active treatment arm versus placebo between the baseline and 36 month visit. The change in MoCA Score ranges from -10 to 6, larger value shows improvement of conditions.</description>
        <time_frame>Baseline to 36 months of treatment</time_frame>
        <population>Intention-to-treat (ITT) population. One participant had missing baseline UPDRS sections while had finished baseline MoCA Score. So MoCA Score had 1 observation more than primary outcomes.</population>
        <group_list>
          <group group_id="O1">
            <title>Isradipine</title>
            <description>Receive Isradipine 5 mg twice daily for 36 months. Isradipine: oral immediate-release capsule of Isradipine 10 mg per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (for Isradipine)</title>
            <description>Receive placebo twice daily for 36 months. Placebo: Sugar Pill manufactured to look like Isradipine but has no active ingredients</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change in MoCA Score</title>
          <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the MoCA Score in the active treatment arm versus placebo between the baseline and 36 month visit. The change in MoCA Score ranges from -10 to 6, larger value shows improvement of conditions.</description>
          <population>Intention-to-treat (ITT) population. One participant had missing baseline UPDRS sections while had finished baseline MoCA Score. So MoCA Score had 1 observation more than primary outcomes.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" lower_limit="-0.36" upper_limit="0.28"/>
                    <measurement group_id="O2" value="-0.07" lower_limit="-0.39" upper_limit="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change in PDQ39 Total Score</title>
        <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the PDQ39 Total Score in the active treatment arm versus placebo between the baseline and 36 month visit. The change in PDQ39 Total Score ranges from -16 to 44, larger value shows worsening of conditions.</description>
        <time_frame>Baseline to 36 months of treatment</time_frame>
        <population>Intention-to-treat (ITT) population. 7 patients had missing PDQ39 scores at the visit of 36 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Isradipine</title>
            <description>Receive Isradipine 5 mg twice daily for 36 months. Isradipine: oral immediate-release capsule of Isradipine 10 mg per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (for Isradipine)</title>
            <description>Receive placebo twice daily for 36 months. Placebo: Sugar Pill manufactured to look like Isradipine but has no active ingredients</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change in PDQ39 Total Score</title>
          <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the PDQ39 Total Score in the active treatment arm versus placebo between the baseline and 36 month visit. The change in PDQ39 Total Score ranges from -16 to 44, larger value shows worsening of conditions.</description>
          <population>Intention-to-treat (ITT) population. 7 patients had missing PDQ39 scores at the visit of 36 months.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.80" lower_limit="1.42" upper_limit="4.18"/>
                    <measurement group_id="O2" value="3.42" lower_limit="2.07" upper_limit="4.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change in Ambulatory Capacity</title>
        <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the Ambulatory Capacity in the active treatment arm versus placebo between the baseline and 36 month visit. The change in Ambulatory Capacity ranges from -4 to 12, larger value shows worsening of conditions.</description>
        <time_frame>Baseline to 36 months of treatment</time_frame>
        <population>Intention-to-treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Isradipine</title>
            <description>Receive Isradipine 5 mg twice daily for 36 months. Isradipine: oral immediate-release capsule of Isradipine 10 mg per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (for Isradipine)</title>
            <description>Receive placebo twice daily for 36 months. Placebo: Sugar Pill manufactured to look like Isradipine but has no active ingredients</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change in Ambulatory Capacity</title>
          <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the Ambulatory Capacity in the active treatment arm versus placebo between the baseline and 36 month visit. The change in Ambulatory Capacity ranges from -4 to 12, larger value shows worsening of conditions.</description>
          <population>Intention-to-treat (ITT) population</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.59" lower_limit="0.34" upper_limit="0.85"/>
                    <measurement group_id="O2" value="0.50" lower_limit="0.25" upper_limit="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change in BDI Total Score</title>
        <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the BDI Total Score in the active treatment arm versus placebo between the baseline and 36 month visit. The change in BDI Total Score ranges from -9 to 22, larger value shows worsening of conditions.</description>
        <time_frame>Baseline to 36 months of treatment</time_frame>
        <population>Intention-to-treat (ITT) population. One participant in Placebo group had missing baseline UPDRS sections while had finished baseline BDI Score. And one participant in Isradipine group had missing BDI score at the visit of 36 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Isradipine</title>
            <description>Receive Isradipine 5 mg twice daily for 36 months. Isradipine: oral immediate-release capsule of Isradipine 10 mg per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (for Isradipine)</title>
            <description>Receive placebo twice daily for 36 months. Placebo: Sugar Pill manufactured to look like Isradipine but has no active ingredients</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change in BDI Total Score</title>
          <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the BDI Total Score in the active treatment arm versus placebo between the baseline and 36 month visit. The change in BDI Total Score ranges from -9 to 22, larger value shows worsening of conditions.</description>
          <population>Intention-to-treat (ITT) population. One participant in Placebo group had missing baseline UPDRS sections while had finished baseline BDI Score. And one participant in Isradipine group had missing BDI score at the visit of 36 months.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" lower_limit="0.05" upper_limit="1.49"/>
                    <measurement group_id="O2" value="1.34" lower_limit="0.63" upper_limit="2.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Risk of Need for Antiparkinsonian Therapy</title>
        <description>Number of participants with need for Antiparkinsonian Therapy.</description>
        <time_frame>Baseline to 36 months of treatment</time_frame>
        <population>Include all 336 patients that were randomized, no matter whether or not completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Isradipine</title>
            <description>Receive Isradipine 5 mg twice daily for 36 months. Isradipine: oral immediate-release capsule of Isradipine 10 mg per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (for Isradipine)</title>
            <description>Receive placebo twice daily for 36 months. Placebo: Sugar Pill manufactured to look like Isradipine but has no active ingredients</description>
          </group>
        </group_list>
        <measure>
          <title>Risk of Need for Antiparkinsonian Therapy</title>
          <description>Number of participants with need for Antiparkinsonian Therapy.</description>
          <population>Include all 336 patients that were randomized, no matter whether or not completed the study.</population>
          <units>participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145" lower_limit="134" upper_limit="153"/>
                    <measurement group_id="O2" value="147" lower_limit="138" upper_limit="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Comparison of the risk of need for antiparkinsonian therapy in Isradipine group to the risk in placebo group.</non_inferiority_desc>
            <p_value>0.073</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Risk of Need for Dyskinesia</title>
        <description>Number of participants with need for Dyskinesia Therapy.</description>
        <time_frame>Baseline to 36 months of treatment</time_frame>
        <population>Include all 336 patients that were randomized, no matter whether or not completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Isradipine</title>
            <description>Receive Isradipine 5 mg twice daily for 36 months. Isradipine: oral immediate-release capsule of Isradipine 10 mg per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (for Isradipine)</title>
            <description>Receive placebo twice daily for 36 months. Placebo: Sugar Pill manufactured to look like Isradipine but has no active ingredients</description>
          </group>
        </group_list>
        <measure>
          <title>Risk of Need for Dyskinesia</title>
          <description>Number of participants with need for Dyskinesia Therapy.</description>
          <population>Include all 336 patients that were randomized, no matter whether or not completed the study.</population>
          <units>participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" lower_limit="17" upper_limit="34"/>
                    <measurement group_id="O2" value="19" lower_limit="12" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Comparison the risk of need for dyskinesia in Isradipine group to the risk in a placebo group.</non_inferiority_desc>
            <p_value>0.21</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>3.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Risk of Need for Fluctuations</title>
        <description>Number of participants with need for Fluctuations Therapy.</description>
        <time_frame>Baseline to 36 months of treatment</time_frame>
        <population>Include all 336 patients that were randomized, no matter whether or not completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Isradipine</title>
            <description>Receive Isradipine 5 mg twice daily for 36 months. Isradipine: oral immediate-release capsule of Isradipine 10 mg per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (for Isradipine)</title>
            <description>Receive placebo twice daily for 36 months. Placebo: Sugar Pill manufactured to look like Isradipine but has no active ingredients</description>
          </group>
        </group_list>
        <measure>
          <title>Risk of Need for Fluctuations</title>
          <description>Number of participants with need for Fluctuations Therapy.</description>
          <population>Include all 336 patients that were randomized, no matter whether or not completed the study.</population>
          <units>participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57" lower_limit="46" upper_limit="70"/>
                    <measurement group_id="O2" value="64" lower_limit="51" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Comparison of the risk of need for antiparkinsonian therapy in Isradipine group to the risk in placebo group.</non_inferiority_desc>
            <p_value>0.35</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.56</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Adjusted Mean Change in UPDRS PIGD Score</title>
        <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the UPDRS PIGD Score in the active treatment arm versus placebo between the baseline and 36 month visit. The change in UPDRS PIGD Score ranges from -1 to 3, larger value shows worsening of conditions.</description>
        <time_frame>Baseline to 36 months of treatment</time_frame>
        <population>Intention-to-treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Isradipine</title>
            <description>Receive Isradipine 5 mg twice daily for 36 months. Isradipine: oral immediate-release capsule of Isradipine 10 mg per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (for Isradipine)</title>
            <description>Receive placebo twice daily for 36 months. Placebo: Sugar Pill manufactured to look like Isradipine but has no active ingredients</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change in UPDRS PIGD Score</title>
          <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the UPDRS PIGD Score in the active treatment arm versus placebo between the baseline and 36 month visit. The change in UPDRS PIGD Score ranges from -1 to 3, larger value shows worsening of conditions.</description>
          <population>Intention-to-treat (ITT) population</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" lower_limit="0.07" upper_limit="0.17"/>
                    <measurement group_id="O2" value="0.10" lower_limit="0.05" upper_limit="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Adjusted Mean Change in UPDRS Tremor Score</title>
        <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the UPDRS Tremor Score in the active treatment arm versus placebo between the baseline and 36 month visit. The change in UPDRS Tremor Score ranges from -1 to 2, larger value shows worsening of conditions.</description>
        <time_frame>Baseline to 36 months of treatment</time_frame>
        <population>Intention-to-treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Isradipine</title>
            <description>Receive Isradipine 5 mg twice daily for 36 months. Isradipine: oral immediate-release capsule of Isradipine 10 mg per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (for Isradipine)</title>
            <description>Receive placebo twice daily for 36 months. Placebo: Sugar Pill manufactured to look like Isradipine but has no active ingredients</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change in UPDRS Tremor Score</title>
          <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the UPDRS Tremor Score in the active treatment arm versus placebo between the baseline and 36 month visit. The change in UPDRS Tremor Score ranges from -1 to 2, larger value shows worsening of conditions.</description>
          <population>Intention-to-treat (ITT) population</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-0.05" upper_limit="0.05"/>
                    <measurement group_id="O2" value="0.01" lower_limit="-0.03" upper_limit="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Adjusted Mean Change in H/Y Stage</title>
        <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the H/Y Stage in the active treatment arm versus placebo between the baseline and 36 month visit. The change in H/Y Stage ranges from -1 to 3, larger value shows worsening of conditions.</description>
        <time_frame>Baseline to 36 months of treatment</time_frame>
        <population>Intention-to-treat (ITT) population. One participant had missing baseline UPDRS sections while had finished baseline H/Y Stage. So H/Y Stage had 1 observation more than primary outcomes.</population>
        <group_list>
          <group group_id="O1">
            <title>Isradipine</title>
            <description>Receive Isradipine 5 mg twice daily for 36 months. Isradipine: oral immediate-release capsule of Isradipine 10 mg per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (for Isradipine)</title>
            <description>Receive placebo twice daily for 36 months. Placebo: Sugar Pill manufactured to look like Isradipine but has no active ingredients</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change in H/Y Stage</title>
          <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the H/Y Stage in the active treatment arm versus placebo between the baseline and 36 month visit. The change in H/Y Stage ranges from -1 to 3, larger value shows worsening of conditions.</description>
          <population>Intention-to-treat (ITT) population. One participant had missing baseline UPDRS sections while had finished baseline H/Y Stage. So H/Y Stage had 1 observation more than primary outcomes.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" lower_limit="0.09" upper_limit="0.22"/>
                    <measurement group_id="O2" value="0.21" lower_limit="0.15" upper_limit="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Adjusted Mean Change in Levodopa</title>
        <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the Levodopa in the active treatment arm versus placebo between the baseline and 36 month visit. The change of LED ranges from -200 to 2000, larger value shows more disability from PD.</description>
        <time_frame>Baseline to 36 months of treatment</time_frame>
        <population>Intention-to-treat (ITT) population. One participant had missing baseline UPDRS sections while had finished baseline Levodopa. So Levodopa had 1 observation more than primary outcomes.</population>
        <group_list>
          <group group_id="O1">
            <title>Isradipine</title>
            <description>Receive Isradipine 5 mg twice daily for 36 months. Isradipine: oral immediate-release capsule of Isradipine 10 mg per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (for Isradipine)</title>
            <description>Receive placebo twice daily for 36 months. Placebo: Sugar Pill manufactured to look like Isradipine but has no active ingredients</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change in Levodopa</title>
          <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the Levodopa in the active treatment arm versus placebo between the baseline and 36 month visit. The change of LED ranges from -200 to 2000, larger value shows more disability from PD.</description>
          <population>Intention-to-treat (ITT) population. One participant had missing baseline UPDRS sections while had finished baseline Levodopa. So Levodopa had 1 observation more than primary outcomes.</population>
          <units>mg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="307" lower_limit="257" upper_limit="356"/>
                    <measurement group_id="O2" value="307" lower_limit="259" upper_limit="355"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Adjusted Mean Change in Levodopa Cumulative</title>
        <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the Levodopa Cumulative in the active treatment arm versus placebo between the baseline and 36 month visit. The change of Levodopa cumulative ranges from 0 to 800000, larger value shows more disability from PD.</description>
        <time_frame>Baseline to 36 months of treatment</time_frame>
        <population>Intention-to-treat (ITT) population. One participant had missing baseline UPDRS sections while had finished baseline Levodopa Cumulative. So Levodopa Cumulative had 1 observation more than primary outcomes.</population>
        <group_list>
          <group group_id="O1">
            <title>Isradipine</title>
            <description>Receive Isradipine 5 mg twice daily for 36 months. Isradipine: oral immediate-release capsule of Isradipine 10 mg per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (for Isradipine)</title>
            <description>Receive placebo twice daily for 36 months. Placebo: Sugar Pill manufactured to look like Isradipine but has no active ingredients</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change in Levodopa Cumulative</title>
          <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the Levodopa Cumulative in the active treatment arm versus placebo between the baseline and 36 month visit. The change of Levodopa cumulative ranges from 0 to 800000, larger value shows more disability from PD.</description>
          <population>Intention-to-treat (ITT) population. One participant had missing baseline UPDRS sections while had finished baseline Levodopa Cumulative. So Levodopa Cumulative had 1 observation more than primary outcomes.</population>
          <units>mg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="471" lower_limit="388" upper_limit="555"/>
                    <measurement group_id="O2" value="508" lower_limit="426" upper_limit="590"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Adjusted Mean Change in Systolic BP, Seated</title>
        <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the Systolic BP, Seated in the active treatment arm versus placebo between the baseline and 36 month visit. The change in Systolic BP, Seated ranges from -65 to 50. larger value shows worsening of conditions.</description>
        <time_frame>Baseline to 36 months of treatment</time_frame>
        <population>Intention-to-treat (ITT) population. One participant had missing baseline UPDRS sections while had finished baseline Systolic BP, Seated. So Systolic BP had 1 observation more than primary outcomes.</population>
        <group_list>
          <group group_id="O1">
            <title>Isradipine</title>
            <description>Receive Isradipine 5 mg twice daily for 36 months. Isradipine: oral immediate-release capsule of Isradipine 10 mg per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (for Isradipine)</title>
            <description>Receive placebo twice daily for 36 months. Placebo: Sugar Pill manufactured to look like Isradipine but has no active ingredients</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change in Systolic BP, Seated</title>
          <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the Systolic BP, Seated in the active treatment arm versus placebo between the baseline and 36 month visit. The change in Systolic BP, Seated ranges from -65 to 50. larger value shows worsening of conditions.</description>
          <population>Intention-to-treat (ITT) population. One participant had missing baseline UPDRS sections while had finished baseline Systolic BP, Seated. So Systolic BP had 1 observation more than primary outcomes.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.11" lower_limit="-8.28" upper_limit="-3.95"/>
                    <measurement group_id="O2" value="1.03" lower_limit="-1.10" upper_limit="3.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Adjusted Mean Change in Diastolic BP, Seated</title>
        <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the Diastolic BP, Seated in the active treatment arm versus placebo between the baseline and 36 month visit. The change in Diastolic BP, Seated ranges from -35 to 25. larger value shows worsening of conditions.</description>
        <time_frame>Baseline to 36 months of treatment</time_frame>
        <population>Intention-to-treat (ITT) population. One participant had missing baseline UPDRS sections while had finished baseline Diastolic BP, Seated. So Diastolic BP had 1 observation more than primary outcomes.</population>
        <group_list>
          <group group_id="O1">
            <title>Isradipine</title>
            <description>Receive Isradipine 5 mg twice daily for 36 months. Isradipine: oral immediate-release capsule of Isradipine 10 mg per day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (for Isradipine)</title>
            <description>Receive placebo twice daily for 36 months. Placebo: Sugar Pill manufactured to look like Isradipine but has no active ingredients</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change in Diastolic BP, Seated</title>
          <description>Efficacy of isradipine to slow progression of Parkinson disease disability to be determined by the change in the Diastolic BP, Seated in the active treatment arm versus placebo between the baseline and 36 month visit. The change in Diastolic BP, Seated ranges from -35 to 25. larger value shows worsening of conditions.</description>
          <population>Intention-to-treat (ITT) population. One participant had missing baseline UPDRS sections while had finished baseline Diastolic BP, Seated. So Diastolic BP had 1 observation more than primary outcomes.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.64" lower_limit="-5.93" upper_limit="-3.36"/>
                    <measurement group_id="O2" value="-0.71" lower_limit="-1.96" upper_limit="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline to 36 months of treatment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Isradipine</title>
          <description>Oral capsule of up to 5 mg of isradipine taken twice daily for 36 months.
Isradipine: Oral capsules Isradipine IR, up to 10 mg, taken twice daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo (for Isradipine)</title>
          <description>Oral capsule taken twice daily for 36 months.
Placebo (for Isradipine): Sugar Pill manufactured to look like Isradipine but has no active ingredients</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>BRADYCARDIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>STRESS CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>SPINA BIFIDA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>APPENDICEAL MUCOCOELE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>DYSPHAGIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CHEST DISCOMFORT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>APPENDICITIS PERFORATED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>BRONCHIOLITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS VIRAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>MENINGITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS ACUTE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>STRESS FRACTURE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>UPPER LIMB FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>HUMERUS FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>SPINAL FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>WRIST FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="170"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>ARTHRITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>COLON CANCER</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>B-CELL LYMPHOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>BREAST CANCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>CHOROID MELANOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>METASTATIC SQUAMOUS CELL CARCINOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>PANCREATIC NEOPLASM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>PITUITARY TUMOUR</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>RECTAL CANCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>THROAT CANCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>TRANSIENT ISCHAEMIC ATTACK</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>APHASIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>BASAL GANGLIA HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>INTRAVENTRICULAR HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>ISCHAEMIC STROKE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>HALLUCINATION, VISUAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>SUICIDAL IDEATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>URINARY RETENTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>MENORRHAGIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>PNEUMONIA ASPIRATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="163" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="154" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>LYMPHOPENIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>PALPITATIONS</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="170"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>TACHYCARDIA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="170"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK FIRST DEGREE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="170"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>VERTIGO</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>EAR DISCOMFORT</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="170"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CATARACT</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="170"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>VISION BLURRED</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="170"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>DRY EYE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="170"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="29" subjects_affected="26" subjects_at_risk="170"/>
                <counts group_id="E2" events="38" subjects_affected="32" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="24" subjects_affected="23" subjects_at_risk="170"/>
                <counts group_id="E2" events="22" subjects_affected="21" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="170"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="170"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>DYSPHAGIA</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="170"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="170"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="170"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="170"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="170"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="170"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>ABDOMINAL DISTENSION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="170"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>DRY MOUTH</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="170"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>SALIVARY HYPERSECRETION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="170"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>OEDEMA</sub_title>
                <counts group_id="E1" events="41" subjects_affected="31" subjects_at_risk="170"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="28" subjects_affected="23" subjects_at_risk="170"/>
                <counts group_id="E2" events="21" subjects_affected="20" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="170"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="170"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>IRRITABILITY</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="26" subjects_affected="23" subjects_at_risk="170"/>
                <counts group_id="E2" events="23" subjects_affected="22" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="170"/>
                <counts group_id="E2" events="20" subjects_affected="11" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="170"/>
                <counts group_id="E2" events="17" subjects_affected="13" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="170"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="170"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="170"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="170"/>
                <counts group_id="E2" events="5" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>TOOTH ABSCESS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="170"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="170"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>EYE INFECTION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="170"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>LOWER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="170"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>TOOTH INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="170"/>
                <counts group_id="E2" events="20" subjects_affected="15" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>LACERATION</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="170"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>MUSCLE STRAIN</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="170"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>LIGAMENT SPRAIN</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>WRIST FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BLOOD CREATINE PHOSPHOKINASE INCREASED</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="170"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>BLOOD CREATININE INCREASED</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="170"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ABNORMAL LOSS OF WEIGHT</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="170"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="170"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>VITAMIN D DEFICIENCY</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="170"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="170"/>
                <counts group_id="E2" events="26" subjects_affected="20" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="20" subjects_affected="17" subjects_at_risk="170"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="170"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="170"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="170"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>JOINT SWELLING</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="170"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL STIFFNESS</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="170"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="170"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>TENDONITIS</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="170"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="170"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>PLANTAR FASCIITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>BURSITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>NECK PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>ROTATOR CUFF SYNDROME</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>OSTEOPOROSIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="170"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>MUSCULAR WEAKNESS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="170"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>BASAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="170"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="170"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="55" subjects_affected="42" subjects_at_risk="170"/>
                <counts group_id="E2" events="30" subjects_affected="26" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="40" subjects_affected="28" subjects_at_risk="170"/>
                <counts group_id="E2" events="19" subjects_affected="17" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>SOMNOLENCE</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="170"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>HYPOAESTHESIA</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="170"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>TREMOR</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="170"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>DYSTONIA</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="170"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="170"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>SCIATICA</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="170"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>RESTLESS LEGS SYNDROME</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="170"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>BRADYKINESIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="170"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>AMNESIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="170"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="170"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>COGNITIVE DISORDER</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>MEMORY IMPAIRMENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" events="22" subjects_affected="19" subjects_at_risk="170"/>
                <counts group_id="E2" events="20" subjects_affected="19" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" events="22" subjects_affected="20" subjects_at_risk="170"/>
                <counts group_id="E2" events="16" subjects_affected="13" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" events="22" subjects_affected="20" subjects_at_risk="170"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>SLEEP DISORDER</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="170"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>RAPID EYE MOVEMENTS SLEEP ABNORMAL</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="170"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>HALLUCINATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>SUICIDAL IDEATION</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="170"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>ABNORMAL DREAMS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="170"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>CONFUSIONAL STATE</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>POLLAKIURIA</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="170"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="170"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>MICTURITION URGENCY</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="170"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>PROTEINURIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>URINARY INCONTINENCE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="170"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>HAEMATURIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>ERECTILE DYSFUNCTION</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="170"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>BENIGN PROSTATIC HYPERPLASIA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="170"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="170"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="170"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>PULMONARY MASS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>RHINORRHOEA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="170"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>NASAL CONGESTION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="170"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="170"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="170"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>ERYTHEMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="170"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>ORTHOSTATIC HYPOTENSION</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="170"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="170"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>FLUSHING</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>HOT FLUSH</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="170"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="170"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Oakes, PhD</name_or_title>
      <organization>University of Rochester Medical Center, Department of Biostatistics and Computational Biology</organization>
      <phone>5852752405</phone>
      <email>david_oakes@urmc.rochester.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

